Objective-Our goal was to examine the influence of indirubin-3Ј-monoxime (I3MO), a natural product-derived cyclin-dependent kinase inhibitor, on vascular smooth muscle cell (VSMC) proliferation in vitro, experimentally induced neointima formation in vivo, and related cell signaling pathways.
R estenosis is the major factor hampering the beneficial effect of angioplasty and stenting. Vascular smooth muscle cell (VSMC) proliferation, next to local vascular inflammation, is a critical factor in neointima formation and vascular lumen loss during restenosis. Thus, one current strategy to maintain proper vascular function after angioplasty is to inhibit VSMC proliferation by targeting cell cycle regulation, eg, by drug-eluting stents. 2, 3 Two products, the rapamycin-eluting Cypher stent and the paclitaxel-eluting Taxus stent, were approved by the US Food and Drug Administration in 2003 and 2004, respectively. Although successfully introduced into the market, there are now concerns about an increased risk of late stent thrombosis. 4 Thus, compounds inhibiting neointima formation with mechanisms differing from those of rapamycin and paclitaxel 5 may have the potential to be efficient with fewer side effects.
Indirubin, a red isomer of indigo, is the active ingredient of the traditional Chinese medicinal formulation Danggui Longhui Wan, used against chronic myelocytic leukemia. 6 Enzyme-based in vitro studies have indicated that indirubin and its derivatives are potent inhibitors of the cyclindependent kinases (CDKs) 1, 2, 4, and 5. 6 -9 Furthermore, different indirubin derivatives showed antitumor activity in several human cancer cells. 6,10 -14 Moreover, for indirubin-3Јmonoxime (I3MO), an in vitro antiinflammatory and anticancer activity had been described on the basis of the inhibition of tumor necrosis factor-induced nuclear factor B activation and the subsequent suppression of antiapoptotic and proproliferative gene expression. 14 The aim of this study was to investigate the potential use of I3MO in the prevention of restenosis. We therefore analyzed a possible effect on platelet-derived growth factor (PDGF)-BB-stimulated VSMC proliferation and endothelial cell function in vitro and examined the influence of I3MO on neointima formation in vivo. We then focused on the signaling pathways that are affected by I3MO.
Methods
An expanded Methods section can be found in the Supplemental Data, available online at http://atvb.ahajournals.org.
Cell Culture
VSMCs were isolated from male Sprague-Dawley rat thoracic aortas by enzymatic digestion and cultured as described. 15 The human endothelial cell line EA.hy 926 (kindly provided by Dr C.-J. Edgell, University of North Carolina, Chapel Hill, NC) was cultivated as described by Leikert et al. 16 Mouse embryonic fibroblasts (MEFs) were grown in DMEM supplemented with 10% FCS and penicillin/streptomycin.
Cell Proliferation Assay
For 5-bromo-2Ј-deoxyuridine (BrdU) incorporation, quiescent cells were incubated with I3MO (1 to 5 mol/L; kindly provided by Laurent Meijer, Roscoff, France, or by Calbiochem); Stattic, a small molecule selectively inhibiting the function of the signal transducer and activator of transcription 3 (STAT3) SH2 domain (3 to 10 mol/L; Sigma-Aldrich); or vehicle (1% dimethyl sulfoxide [DMSO]) 30 minutes before stimulation with PDGF-BB (20 ng/mL) or thrombin (0.5 U/mL; Calbiochem). BrdU was added 1 hour later, and its incorporation was determined 23 hours after addition of the respective stimulus, according to the manufacturer's instructions (Roche Diagnostics).
Cell Cycle Analysis
Quiescent cells were preincubated with I3MO (3 or 5 mol/L) or vehicle (1% DMSO) for 30 minutes. PDGF-BB (20 ng/mL) was added, and 16 hours (in the case of VSMCs) or 11 hours (in the case of MEFs) later, cells were harvested and the cell cycle was analyzed as described. 17
[ 14 C]L-Arginine/[ 14 C]L-Citrulline Conversion Assay
Citrulline is produced from arginine by endothelial nitric oxide synthase (eNOS) in equimolar amounts to NO and can thus serve as a surrogate marker of NO production. The assay was performed as previously described. 16 
Femoral Artery Cuff Model
Male C57Bl/6 mice at 8 to 12 weeks of age were subjected to cuffing of the femoral artery. The surgical procedure was performed as described previously. 18 Briefly, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), a longitudinal incision was made at the internal side of the right leg, and the right femoral artery of mice was dissected for 3 mm length from its surroundings (femoral nerve and femoral vein). A nonconstrictive polyethylene cuff (PE-50; inner diameter, 0.58 mm; outer diameter, 0.965 mm; length, 2 mm; Becton-Dickinson) was cut longitudinally, placed loosely around the right femoral artery, and filled with F-127 pluronic gel (Sigma-Aldrich) containing I3MO. This gel was prepared in advance by mixing 760 L of cold 40% (wt/vol) F-127 pluronic gel dissolved in sterile water with 40 L of 100 mmol/L I3MO dissolved in DMSO. Cuffs filled with F-127 pluronic gel but lacking I3MO were used in control animals. The cuff was then closed up with 2 6-0 ligature knots (USP: 6-0, Metric: 0.7, Ethicon Vicryl, Johnson & Johnson International). The skin incision was then closed with 3 sutures (USP: 6-0, Metric: 0.7, Ethicon Vicryl, Johnson & Johnson Intl.). Three, 7, 14, or 28 days after placing of the cuffs, mice were anesthetized and subsequently perfused by cardiac puncture with EDTA-PBS (1.75 mg/mL). After perfusion, a 2-cm longitudinal incision was made in the internal side of the leg, and the cuffed femoral artery was removed and embedded for cryo-sectioning. Animal care and all experimental procedures were approved by the Animal Experimental Committee of the Medical University of Vienna and by the Austrian Ministry of Science (license no. 1321/115 and 66.009/0103-C/Gl/2007).
Immunocytochemistry
Frozen sections of 5 to 7 m thickness were fixed with precooled acetone at Ϫ20°C for 2 min and blocked with 5% normal goat serum in Primary Antibody Dilution Buffer (DAKO) for 1 hour. For quantification of VSMCs, the monoclonal (clone1A4) anti-smooth muscle actin antibody conjugated to either fluorescein isothiocyanate or Cy3 (Sigma-Aldrich) was applied for 12 hours at 4°C. For detection of phospho-STAT3, sections were pretreated with periodic acid (4 mg/100 mL), incubated overnight at 4°C with the rabbit monoclonal antibody D3A7 (Cell Signaling Technology, Danvers, Mass), washed, incubated for 1 hour at room temperature with Power Vision polymer (Immunologic, Duiven, the Netherlands), and subsequently developed with DAB/H 2 O 2 . For Ki-67, the rabbit monoclonal antibody clone SP6 (Thermo Scientific, Fremont, Calif) was applied overnight at 4°C followed by the Alexa 488 -labeled goat anti-rabbit antibody (Invitrogen) applied for 1 hour at room temperature. After counterstaining with 4Ј,6-diamidino-2-phenylindole (Sigma-Aldrich) for 10 minutes, the samples were mounted using Geltol (Thermo-Shandon) and visualized on an Olympus AX70 microscope (Olympus Europe GmbH). Digital images were recorded using either an F-View II or a ColorView III camera and morphometrically assessed using the software package AnalySiS Pro (Soft Imaging System).
SDS-PAGE and Immunoblotting
Serum-starved VSMCs were preincubated with I3MO (0.1 to 5 mol/L), wortmannin, U0126, SU6656, or AG490 at the indicated concentrations or vehicle (1% DMSO) for 30 minutes and then stimulated with PDGF-BB (20 ng/mL), interferon (IFN)-␥ (20 ng/mL), or thrombin (0.5 U/mL) for the indicated times. Protein isolation and immunoblotting were performed essentially as described by Haider et al 17 All antibodies used were from New England BioLabs with the exception of anti-␣-tubulin (Santa Cruz Biotechnology Inc) and a horseradish peroxidase-conjugated goat antimouse secondary antibody (Upstate). Proteins were visualized using the ECL reagent and an LAS-3000 luminescent image analyzer (Fujifilm) with AIDA software (Raytest).
Transient Transfection
Expression vectors (1 g), ie, Stat3 Flag pRc/CMV (Addgene plasmid 8707) encoding the wild-type or Stat3-C Flag pRc/CMV (Addgene plasmid 8722) encoding the constitutively active form of STAT3, 19, 20 were used for transfection of MEFs grown in 6-well plates using Fugene HD (Roche Diagnostics) as a transfection reagent and following the manufacturer's instructions.
Statistical Analysis
Statistical analysis was performed by t test or 1-way ANOVA followed by a Dunnett multiple comparison test. The number of experiments is given in the figure legends, and a probability value Ͻ0.05 was considered significant. All tests were performed using GraphPad PRISM software, version 4.03.
Results

I3MO Inhibits PDGF-BB-Induced VSMC Proliferation by Arresting Cells in G 0 /G 1 Phase and Does Not Impair Endothelial Function
First, we tested I3MO for its antiproliferative activity in PDGF-activated VSMCs. Measurement of DNA synthesis via BrdU incorporation showed that PDGF-BB (20 ng/mL, 23 hours) increased DNA synthesis Ϸ3-fold and that I3MO inhibited cell proliferation dose-dependently ( Figure 1A ). I3MO (3 or 5 mol/L)-treated cells showed no signs of apoptosis as measured by the absence of nuclei with a subdiploid DNA content or nuclear fragmentation (data not shown). Cell cycle analysis by flow cytometry revealed an arrest of I3MO (3 or 5 mol/L)-treated VSMCs in G 0 /G 1 phase ( Figure 1B ). To exclude that I3MO causes a DNA replication block in early S phase, which is difficult to distinguish from a G 0 /G 1 arrest by flow cytometry, we arrested cells using the reversible DNA-polymerase inhibitor aphidicolin (1 mol/L) in early S phase. Subsequent treatment of released cells (after washout of aphidicolin) with I3MO did not prevent DNA synthesis, as shown by newly incorporated BrdU (Supplemental Figure I) . Hyperphosphorylation of the retinoblastoma protein (Rb), an important regulator at the G 1 /S phase transition, is required for S phase entry. 21 As expected, stimulation of VSMCs with PDGF-BB alone led to a time-dependent increase in phosphorylation of Rb on S807/811, first detectable after 6 hours. Cells treated with I3MO kept Rb in a hypophosphorylated state ( Figure  1C ), again confirming cell cycle arrest in G 0 /G 1 phase. eNOS represents an enzyme crucial for antiatherosclerotic endothelial function 22 and for NO-dependent inhibition of VSMC proliferation. 23, 24 To exclude a negative effect of I3MO on endothelial function as judged by eNOS activity, human endothelial EA.hy926 cells were exposed to I3MO (3 mol/L) or, as a positive control, to ascorbic acid (100 mol/L) for 24 hours, and L-citrulline production was measured. Most interestingly, I3MO slightly but significantly increased eNOS activity to Ϸ1.3-fold ( Figure 1D ). Moreover, I3MO had no negative influence on endothelial cell viability (Supplemental Figure II) .
I3MO Prevents Neointima Formation in a Mouse Femoral Artery Cuff Model
Next, we examined whether I3MO reduces neointima formation in vivo. The femoral artery cuff model has been used previously to study the process of restenosis in mice. 25, 26 To examine the effect of locally applied I3MO on cuff-induced stenosis of an artery, we dissolved the substance in F-127 pluronic gel and placed the gel into the cuff surrounding the femoral artery. Twenty-eight days after placing the cuff, we observed an inhibitory effect of I3MO on cuff-induced neointima formation. As depicted in Figure 2A , 2B, and 2D, I3MO was capable of attenuating the development of a neointima significantly without affecting the thickness of the media. In consequence, the neointima/media ratio was significantly reduced by more than 50% ( Figure 2C ).
I3MO Suppresses Activation of STAT3 but Not of Mitogen-Activated Protein Kinases and Akt
We then analyzed the molecular mediators of the antiproliferative activity of I3MO in VSMCs. In the presence of calf serum (10%), no significant inhibition of cell proliferation was observed in response to 1 to 10 mol/L I3MO (data not shown). This indicates that I3MO at concentrations below 10 mol/L does not block cell cycle entry via a direct inhibition of CDKs but rather interferes with a step further upstream in the mitogenic response to PDGF.
The kinase Akt and the mitogen-activated protein kinases Erk1/2 or p38 MAPK are critically involved in VSMC proliferation. 27 As shown in Figure 3A 3-kinase inhibitor wortmannin and the MEK1/2 inhibitor U0126 inhibited activation of Akt and Erk1/2, respectively. Neither treatment with PDGF-BB nor treatment with I3MO changed the total protein levels of Akt, Erk1/2, or p38 MAPK . On ligand binding, tyrosine phosphorylation of the PDGF receptor was only moderately impaired by I3MO (Supplemental Figure III) . These data exclude the intrinsic tyrosine kinase of PDGF receptor as the main and immediate target of I3MO.
Signal transducer and activator of transcription 3 (STAT3) is thought to participate in PDGF-induced cell proliferation. 28, 29 Indeed, stimulation of VSMCs with PDGF-BB (20 ng/mL, 10 minutes) led to a strong phosphorylation of Y705 in STAT3, a critical residue for dimerization of STAT3 and subsequent translocation into the nucleus. The Src family kinase inhibitor SU6656 but not the JAK2 inhibitor AG490 was able to abrogate activation of STAT3, indicating a Src-dependent but JAK2-independent phosphorylation of STAT3 on PDGF treatment in VSMCs. Preincubation with I3MO (3 or 5 mol/L) completely abolished phosphorylation of Y705 ( Figure 3A , lower panel). Total amounts of STAT3 were not affected by I3MO.
I3MO Inhibits STAT3 Phosphorylation in a Dose-Dependent but Stimulus-Independent Manner
I3MO suppressed PDGF-induced STAT3 phosphorylation dose-dependently, first observed at a concentration of 0.3 mol/L ( Figure 3B , upper panel) To examine whether STAT3 inhibition by I3MO is stimulus dependent, we activated VSMCs with IFN-␥ (20 ng/mL), a mediator of proatherogenic processes 30, 31 and known activator of STAT proteins. 32 Treatment with IFN-␥ resulted in a clear increase in phosphorylation of Y705 ( Figure 3B, middle panel) , which was inhibited by I3MO in a dose-dependent manner. Moreover, STAT3 phosphorylation induced by thrombin (0.5 U/mL), another potent mitogen in VSMCs, 33 was also completely blunted by I3MO ( Figure 3B Finally, to rule out that inhibition of STAT3 phosphorylation occurs only in the first hour after stimulation, we performed long-term experiments up to a period of 18 hours. I3MO (3 or 5 mol/L) kept STAT3 hypophosphorylated throughout the entire incubation time (Supplemental Figure V ).
STAT3 Inhibition Leads to Inhibition of Cell Proliferation
To underline that inhibition of STAT3 phosphorylation is sufficient to inhibit VSMC proliferation, we used Stattic, a selective inhibitor of STAT3 phosphorylation and dimerization. 34 Incubation with either Stattic or I3MO prevented PDGF-and thrombin-mediated VSMC proliferation in a dose-dependent manner as evidenced by reduced BrdU incorporation ( Figure 4A ). Like I3MO, Stattic did not inhibit ERK1/2, p38 MAPK or AKT phosphorylation (data not shown). Moreover, MEFs expressing a constitutively active form of STAT3 ( Figure 4B ) were able to escape the cell cycle arrest induced by I3MO in cells expressing wild-type STAT3. Whereas I3MO significantly reduced the percentage of wildtype cells moving to S phase after PDGF stimulation, constitutively active cells remained unaffected by I3MO ( Figure  4C ). These findings underline the notion of activated STAT3 as an important mediator of VSMC proliferation 33, 35 and suggest that inhibition of STAT3 phosphorylation is indeed the molecular mechanism underlying the antiproliferative effect of I3MO.
I3MO Inhibits STAT3 Phosphorylation In Vivo
In a next step, our goal was to confirm the correlation between reduced STAT3 phosphorylation and reduced VSMC proliferation in our in vivo model. By immunocytochemical staining, we could show that I3MO-treated arteries displayed a reduced number of phosphoSTAT3 ϩ cells at days 3, 7, and 14 after cuff placement compared with arteries treated with vehicle ( Figure 5A and 5B) . The observed decrease in STAT3 phosphorylation was reflected by a reduced number of proliferating Ki67-positive cells ( Figure  5C and 5D) .
These data strongly indicate that the phosphorylation of STAT3 serves as a major target of I3MO both in vitro and in vivo. 
Discussion
The present study shows that I3MO, a derivative of the natural product indirubin, potently inhibits DNA synthesis in PDGF-activated VSMCs by arresting cells in the G 1 phase of the cell cycle and significantly reduces neointima formation when applied locally in an animal cuff-induced neointima model. In contrast to previous studies that characterized I3MO as a potent CDK inhibitor in vitro, 6 -9 we show that I3MO acts upstream of CDKs by completely abrogating PDGF-induced STAT3 activation in VSMCs. Importantly, I3MO also inhibited IFN-␥-and thrombin-mediated STAT3 activation, whereas none of the typical growth factor-induced signaling pathways, such as Akt or the mitogen-activated protein kinases Erk1/2 or p38 MAPK , were affected. Interestingly, in the mouse femoral artery cuff model also, where I3MO reduced neointima formation, the number of phospho-STAT3-positive cells was reduced, correlating with a reduced number of proliferating cells. Endothelial function as judged by eNOS activity was not negatively affected by I3MO. The observed strong interference of the known CDK inhibitor I3MO with the STAT3 signaling pathway in VSMCs was rather unexpected, although a previous study has shown that some indirubin derivatives are able to block constitutive STAT3 signaling in tumor cells. 12 In tumorigenesis, a role for STAT proteins is quite well established. 36 However, less is known regarding STAT proteins and their role in cardiovascular diseases. With respect to neointima formation and vascular remodeling, Seki et al showed that JAKs and STATs are induced in medial and neointimal VSMCs after vascular injury and that JAK inhibition leads to reduced STAT phosphorylation, reduced neointimal VSMC replication, and neointima formation. 37 The same group also demonstrated that adenoviral overexpression of a dominant negative STAT3 in a balloon-injury artery model reduces neointimal VSMC proliferation and neointima formation. 35 A more recent article by Wang et al suggested a strong role for the interleukin-6/gp130/STAT3 signaling in vascular remodeling and neointima formation. 38 Moreover, STAT3 activation has recently been shown to be involved in VSMC inflammation and vascular remodeling on injury. 39 All these studies indicate that in fact inhibition of the JAK-STAT pathway could affect neointima formation. In our study, we confirmed a role for STAT3 inhibition by I3MO in reducing neointima formation in vivo and by inhibiting PDGF-induced VSMC proliferation in vitro.
I3MO abrogated not only PDGF-induced STAT3 phosphorylation but also STAT3 activation in response to IFN-␥ and thrombin. This is of special importance because the proinflammatory cytokine IFN-␥ plays a central role in atherosclerosis, restenosis, and neointima formation. 40 -42 Although different mechanisms for the mitogenic and motogenic activity of thrombin for VSMCs were suggested, there are data indicating that STAT3 also plays a role for thrombin-induced cell motility and proliferation. [43] [44] [45] Interference with the STAT signaling pathway is a mechanism that differs considerably from those shown for established vascular antiproliferative drugs, such as rapamycin or paclitaxel. Paclitaxel inhibits microtubule dynamics, leading predominantly to M phase arrest. Because paclitaxel inter-feres at a stage of the cell cycle where cells are supposed to divide, proapoptotic mechanisms are likely to occur. 5 In combination with impaired reendothelialization, this might be detrimental for arterial wound healing, and it possibly increases the risk for thrombosis. 5 In contrast, I3MO did not induce apoptosis in the effective antiproliferative range of concentrations. Rapamycin inhibits mTOR, the mammalian target of rapamycin, arresting cells in G 1 phase via elevated levels of p27 KIP , a CDK inhibitor. In addition, rapamycin has an immunosuppressive activity that is thought to be beneficial for the local suppression of inflammatory responses. 5 I3MO, similar to rapamycin, arrests VSMCs in G 1 phase and seems to have an antiinflammatory activity by interfering with IFN-␥ signaling and inhibiting tumor necrosis factor-␣induced nuclear factor B activation, as demonstrated in human leukemic cells. 14 We show here that I3MO significantly reduces neointima formation in a mouse femoral artery model by inhibition of phosphorylation of STAT3 as demonstrated in vitro and in vivo, suggesting I3MO as a promising lead compound that warrants further investigation regarding its potential use to prevent neointima formation.
